ERAS

Erasca, Inc. [ERAS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ERAS Stock Summary

Top 10 Correlated ETFs

ERAS

Top 10 Correlated Stocks

ERAS

In the News

ERAS Financial details

Company Rating
-
Market Cap
319.65M
Income
-121.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
126
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.42
Forward P/E
-
PEG
0.24
P/S
-
P/B
-0.55
P/C
-
P/FCF
-2.54
Quick Ratio
11.1
Current Ratio
11.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-57.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
27.89%
SMA50
327.27%
SMA100
516.39%
Inst Own
-
Inst Trans
-
ROA
-53%
ROE
74%
ROC
-0.12%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.51-3.375
52W High
+354%
52W Low
+1262%
RSI
53.1
Rel Volume
6.45
Avg Volume
813.68K
Volume
5.25M
Perf Week
-9.92%
Perf Month
32.1%
Perf Quarter
640.22%
Perf Half Y
778.71%
-
-
-
-
Beta
1.104
-
-
Volatility
0.71%, 1.57%
Prev Close
-7.03%
Price
13.62
Change
-10.98%

Something similar

Top by Market Cap
LLY.DE
MSFT
VFINX
JPM
DHR-PB
Top Correlated ETFs
TDTT
STIP
ENFR
VTIP
MLPX
Top Correlated Stocks
IOVA
RAMP
DATAPATTNS.NS
BOS.TO
QBR-B.TO
Similar Market Cap
NKTR
IGB.TO
PBRT.L
DBPG.DE
XPDB

Company Profile

Healthcare Biotechnology
  • Volume Average 813.68K
  • Market Capitalization 319.65M
  • Employee 126
  • CEO Dr. Jonathan E. Lim M.D.
  • Headquarters San Diego,CA,US
  • IPO Date 2021-07-16
  • Website https://www.erasca.com

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.